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Abstract 
Immunoparalysis is a common cause of death for critical care patients with sepsis, during which 
comprehensive suppression of innate and adaptive immunity plays a significant pathophysiological 
role. Although the underlying mechanisms are unknown, damage-associated molecular pattern 
molecules (DAMPs) from septic tissues might be involved. Therefore, we surveyed sera from septic 5 
patients for factors that suppress the innate immune response to DAMPs, including adenosine 
triphosphate (ATP), monosodium urate, and high mobility group box-1. Macrophages, derived from 
THP-1 human acute monocytic leukemia cells, were incubated with each DAMP, in the presence or 
absence of sera that were collected from critically ill patients. Secreted cytokines were then 
quantified, and cell lysates were assayed for relevant intracellular signaling mediators. Sera from 10 
septic patients who ultimately did not survive significantly suppressed IL-1β production only in 
response to extracellular ATP. This effect was most pronounced with sera collected on day 3, and 
persisted with sera collected on day 7. However, this effect was not observed when THP-1 cells 
were treated with sera from survivors of sepsis. Septic sera collected at the time of admission (day 
1) also diminished intracellular levels of inositol 1,4,5-triphosphate and cytosolic calcium (P < 15 
0.01), both of which are essential for ATP signaling. Finally, activated caspase-1 was significantly 
diminished in cells exposed to sera collected on day 7 (P < 0.05). In conclusion, the sera of septic 
patients contain certain factors that persistently suppress the immune response to extracellular ATP, 
thereby leading to adverse clinical outcomes.  
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Introduction 
Sepsis, a systemic inflammatory response to infection, causes multi-organ failure, severe 
morbidity, and death (Liu et al. 2014; Kissoon and Uyeki 2016); endothelial dysfunction, metabolic 
changes, and overwhelming or hyperinflammatory innate immune responses to pathogen-associated 
molecular patterns have been proposed to be the main underlying mechanisms of this condition. 5 
Sepsis-induced immunoparalysis, in which both innate and adaptive immunity are suppressed 
(Frazier and Hall 2008; Hotchkiss et al. 2013), is also an active focus of research, since it increases 
the risk of secondary infections and promotes adverse clinical outcomes (Hotchkiss et al. 2013). Of 
note, Fattahi and Ward (2017) identified universal mechanisms that drive sepsis-induced 
immunosuppression, including reduced antigen processing by innate immune cells, the 10 
accumulation of regulatory T cells, and the abundant production of immunosuppressive factors. 
Inflammatory responses mediated by innate immunity generally promote healing and 
microbial clearance, although the massive production of pro- and anti-inflammatory cytokines by 
macrophages might also lead to pathological inflammation. Primary inflammatory cytokines 
include tumor necrosis factor-α, interleukin-1β (IL-1β), and IL-6, which mediate acute 15 
inflammation (Trikha et al. 2003) but also cause cell injury and cell death (Kim et al. 2011). In 
turn, injured tissues and dying cells generate damage-associated molecular patterns (DAMPs), 
which then act on various inflammasomes to promote or suppress inflammation (Guo et al. 2015). 
However, the roles of these DAMPs in sepsis are unknown. 
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DAMPs stimulate nucleotide oligomerization domain-like receptor (NLR) inflammasomes 
to activate caspase-1, which then cleaves pro-IL-1β to generate mature, bioactive IL-1β (Chen and 
Nuñez 2010; Takeuchi and Akira 2010). One such inflammasome is NLR protein 3 (NLRP3), 
which contains an ASC-PYCARD domain (Cai et al. 2014; Lu et al. 2014) and is particularly 
sensitive to a wide variety of DAMPs including adenosine triphosphate (ATP), crystalline 5 
substances, nucleic acids, and hyaluronan (Lamkanfi and Dixit 2014; Vanaja et al. 2015). In this 
study, we screened sera from septic patients for the ability to alter innate immune responses to 
DAMPs and inflammasomes, with the goal of defining mechanisms that drive immunoparalysis 
during sepsis. 
 10 
Materials and Methods 
Study design and collection of human sera 
This study was approved by the Ethics Committee Review Board of Hiroshima University, 
and was compliant with the Declaration of Helsinki regarding the review and publication of patient 
data. Sera were collected from patients admitted to the Department of Emergency and Critical Care 15 
Medicine, Hiroshima University Hospital for sepsis, with consent from patients or from a family 
member. Sepsis was diagnosed according to the American College of Chest Physicians and the 
Society of Critical Care Medicine Consensus Conference (Singer et al. 2016). For comparison, sera 
were also collected with consent from patients > 50 years of age who suffered trauma from any 
cause, as well as from five healthy volunteers. On the day of admission (day 1), as well as day 3 and 20 
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day 7, peripheral blood samples were collected into evacuated non-EDTA VENOJECT® II tubes 
(Terumo, Somerset, NJ, USA) through an indwelling arterial line or a peripheral vein. Blood 
samples were allowed to clot for ≥ 30 min at room temperature, and sera were obtained by 
centrifugation at 3,000 u g for 10 min and then stored at −80 °C for further analysis. 
 5 
Reagents  
Human acute monocytic leukemia THP-1 monocytes (TIB-20) were obtained from the 
American Type Culture Collection (Manassas, VA, USA). Phorbol 12-myristate 13-acetate, ATP, 
and monosodium urate crystals were purchased from Sigma-Aldrich (St. Louis, MO, USA). High 
mobility group box 1 (HMGB1) was obtained from Thermo Fisher Scientific (Illkirch, France), and 10 
trypsin-EDTA was acquired from Gibco/Thermo Fisher (Burlington, ON, Canada). 
 
Human inflammatory cytokine panel 
Sera were assayed for 13 inflammatory cytokines using a LegendplexTM human 
inflammation panel (BioLegend, San Diego, CA, USA), following the manufacturer’s protocol. The 15 
panel consists of bead-based immunoassays, similar to sandwich immunoassays, with the lowest 
limit of quantification being approximately 0.6 pg/mL. Data were acquired using a BD 
FACSCaliburTM (Becton, Dickinson Biosciences, San Jose, CA, USA) and analyzed with 
LegendplexTM Data Analysis Software (BioLegend). 
 20 
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Cell culture and response to DAMPs 
THP-1 monocytes were seeded at 1 × 105 cells/well in 24-well plates containing RPMI 1640 
(Gibco) media with 10 % fetal bovine serum (Gibco) and 100 U/mL penicillin/streptomycin 
(Thermo Fisher) and differentiated for 48 h with 0.5 μM phorbol 12-myristate 13-acetate. Media 
were then removed, and cells were exposed to sera diluted 60u, with or without DAMPs including 5 
2.0 mM ATP (Laliberte et al. 1999), 200 μg/mL monosodium urate (Gicquel et al. 2015), and 1 
μg/mL HMGB1 (Robert et al. 2010); this incubation proceeded for 8 h. The resulting culture 
supernatant was collected, centrifuged at 40,000 rpm for 10 min at 4 °C, and transferred to 1.5-mL 
centrifuge tubes for immediate quantification of IL-1β or stored at −20 °C for further experiments. 
For the vehicle control condition, THP-1 macrophages were incubated with serum-free RPMI 10 
without supplementation (untreated). In addition, cells were washed twice with cold 
phosphate-buffered saline (Gibco) and collected by scraping them into cell lysate buffer (Abcam, 
Cambridge, U.K.) following the product instructions. Lysates were then cleared of debris and 
transferred to 1.5-mL centrifuge tubes for immediate quantification of intracellular signaling 
mediators or stored at −20 °C for further experiments. 15 
 
Cell viability 
Cell viability was assessed by annexin V/propidium iodide staining (eBioscience, San Diego, 
CA, USA). Briefly, cells were harvested with trypsin-EDTA, suspended in staining buffer, stained 
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for 20 min with annexin V and propidium iodide, and analyzed using a BD FACSCaliburTM and BD 
CellQuestTM Pro (Becton, Dickinson Biosciences, San Jose, CA, USA). 
 
P2X7 channel uptake 
YO-PRO-1, a 629-Da fluorescent nucleic acid dye that is transported across the cell 5 
membrane by P2X7, was used to quantify the uptake of extracellular ATP, as previously described 
(Cankurtaran-Sayar et al. 2009). In brief, cells were collected with trypsin-EDTA, centrifuged at 
1,500 rpm for 5 min, washed once with cold phosphate-buffered saline, and stained with 2 μM 
YO-PRO-1 (Invitrogen, Carlsbad, CA, USA) for 30 min in the dark. The mean fluorescence 
intensity was then analyzed using a BD FACSCaliburTM and BD CellQuestTM Pro (Becton, 10 
Dickinson Biosciences, San Jose, CA, USA). 
 
Quantification of cytokines and mediators of intracellular signaling 
IL-1β, intracellular pro-IL-1β, and caspase-1 p20 were quantified using a BD OptEIATM Set 
for human IL-1β (Becton, Dickinson Biosciences), a Human Pro-IL-1β/IL-1F2 Immunoassay Kit 15 
(R&D Systems, Minneapolis, MN, USA), and a Human Caspase-1/ICE Immunoassay Kit (R&D 
Systems, Minneapolis, MN, USA), respectively. All three kits are based on sandwich 
enzyme-linked immunosorbent assays and were used according to the manufacturer’s instructions. 
Inositol 1,4,5-triphosphate (Cusabio, Wuhan Hi-tech Medical Devices Park, Wuhan, China) and 
cyclic AMP (R&D Systems, Minneapolis, MN, USA) were quantified by competitive 20 
9 
 
enzyme-linked immunosorbent assays. For all assays, readings at 450 nm were obtained using a 
spectrophotometer (Perkin Elmer, Courtaboeuf, France). Cytosolic calcium was quantified using the 
Calcium Detection Assay Kit (Abcam), in which a chromogenic complex that is formed between 
calcium ions and O-cresolphthalein was quantified by spectrophotometry at 575 nm using a 
Varioskan Flash (Thermo Scientific, Illkirch, France). 5 
 
ATP assays 
Extracellular and intracellular ATP levels were quantified using an ATP Detection Kit 
(Invitrogen) according to the manufacturer’s instructions. Readings at 450 nm were obtained using 
a spectrophotometer (Perkin Elmer, Courtaboeuf, France). 10 
 
Statistical analysis 
Data were analyzed using SPSS 22 (IBM, Armonk, NY, USA). Categorical variables were 
compared by the Fisher’s exact test, whereas multiple groups of normally distributed, unpaired data 
on an interval scale were tested by a one-way analysis of variance, and then compared pairwise by 15 
post hoc analysis. A Mann–Whitney’s U test or F2 test was used for pairwise comparison of 
non-normally distributed, unpaired data on an interval scale. P < 0.05 was considered statistically 
significant. Continuous variables are reported or plotted in bar graphs as the mean ± standard 
deviations, with bold lines indicating median values, boxes indicating interquartile ranges, and 
whiskers indicating extreme values within 2.5-fold of the interquartile range around the median. 20 
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Results 
Cytokine and chemokine profiles of sera from septic patients 
The characteristics of critically ill patients and healthy volunteers are listed in Table 1. 
Septic patients were further stratified as shown in Table 2. Because of inflammation, serum levels 5 
of C-reactive protein and lactate at the time of patient admission (day 1) were significantly higher in 
septic patients than in trauma patients, as previously observed during the acute phase (Póvoa 2002; 
Jain et al. 2011; Jin et al. 2014; Markanday 2015). Similarly, IL-1β, IL-6, IL-8, IL-10, IL-18, 
interferon-D, macrophage inflammatory protein-1, and tumor necrosis factor-α were significantly 
elevated in sera from septic patients as compared with those in sera from trauma patients (Fig. 1); in 10 
contrast, interferon-γ, IL-23, IL-12, IL-17, and IL-33 were barely detectable in < 30% of all serum 
samples (data not shown). These observations are concordant with previous studies on innate 
immunity during acute-phase sepsis, during which pro- and anti-inflammatory responses were both 
found to be exaggerated (Póvoa 2002; Giannoudis et al. 2004; Kirchhoff et al. 2009; Jaffer et al. 
2010; Saraiva and O'Garra 2010; Jain et al. 2011; Jin et al. 2014; Reikeras et al. 2014). 15 
 
DAMP-specific anti-inflammatory activity of sera from septic patients 
After exposing THP-1 macrophages to patient sera, the resulting culture supernatant was 
tested for IL-1β levels. Strikingly, sera collected from septic patients at the time of admission 
tended to suppress the in vitro production of IL-1β by macrophages; however, sera from trauma 20 
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patients or healthy volunteers did not (Fig. 2A). This result suggests that septic sera, collected at the 
time of patient admission, are likely predominantly anti-inflammatory, despite enhanced levels of 
both pro- and anti-inflammatory cytokines. Further, upon stimulation with each known DAMP in 
the presence of patient sera, IL-1β production was suppressed only in response to extracellular ATP 
(Fig. 2B), but not in response to monosodium urate or HMGB1 (Fig. 2C, D). Similar analysis of 5 
septic sera collected on days 3 and 7 after admission indicated prominent suppression of 
ATP-induced IL-1β production by sera collected on day 3. This activity persisted with sera collected 
on day 7 from patients who ultimately did not survive; however, this was not the case when using 
sera collected on day 7 from patients who survived (Fig. 3A). As with sera collected on day 1, day 3, 
and day 7, these trends were not observed in macrophages stimulated with monosodium urate (Fig. 10 
3B). The observed loss of ATP-induced IL-1β production was not due to serum-induced apoptosis, 
as cell viability after 8 h was comparable among all cells (data not shown). Therefore, we 
hypothesize that sera from septic patients have inherent anti-inflammatory functions and might 
contain factor(s) that suppress the response to extracellular ATP. 
 15 
Possible anti-inflammatory mechanisms of septic sera 
 Extracellular ATP is known to trigger IL-1β production in macrophages by acting on NLRP3 
inflammasomes via purinergic pathways that depend on P2X, P2Y, and adenosine P1 receptors 
(Baron et al. 2015). For example, extracellular ATP binds P2X7 and thereby elicits cytosolic K+ 
efflux and extracellular Na+/Ca2+ influx. Of note, P2X7 also transports large molecular weight tracers 20 
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into cells, including YO-PRO-1, at millimolar extracellular ATP concentrations. ATP and adenosine 
diphosphate also act through P2Y, thereby generating inositol 1,4,5-triphosphate and boosting 
cytosolic calcium. Finally, adenosine, a product of ATP hydrolysis, acts through adenosine 
receptors to form cyclic AMP, which in turn suppresses NLRP3. In any case, NLRP3 activation by 
purinergic receptors activates caspase-1, which processes pro-IL-1β into mature IL-1β. Hence, we 5 
hypothesized that the observed loss of ATP-induced IL-1β production could be due to ATP 
hydrolysis by ATPases in sera from septic patients, inhibition of P2X7, or inhibition of NLRP3. 
 
ATPase activity in sera from septic patients is negligible 
Using a luciferase-based assay, we compared ATP levels in supernatants after incubating 10 
macrophages with ATP and the sera from healthy donors, trauma patients, or septic patients. We 
found that ATP levels were similar among these groups (Fig. 4A). In addition, residual ATP in sera 
probably did not affect macrophage activity since these samples were diluted such that ATP levels 
would be negligible before addition to cells (Fig. 4B). These results suggest that ATPase activity in 
patient sera, if any, did not significantly affect IL-1β production in response to extracellular ATP. 15 
 
Septic sera from non-survivors activates the P2X7 channel 
As previously reported, the uptake of YO-PRO-1 or other large, positively charged tracers is 
a direct measure of P2X7 activity (Cankurtaran-Sayar et al. 2009; Baron et al. 2015). Thus, THP-1 
macrophages stimulated with ATP and patient sera were stained with YO-PRO-1 and analyzed by 20 
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flow cytometry. The mean fluorescence intensity was comparable among macrophages treated with 
sera from healthy controls, trauma patients, or septic patients (Fig. 4C). However, this was higher in 
macrophages treated with sera collected on days 1 and 7 from patients who did not survive than in 
cells treated with sera from septic patients who survived (P < 0.05; Fig. 4D). In the presence of 10 
μM A-740003, a specific inhibitor of P2X7, the mean fluorescence intensity was dramatically 5 
diminished in all cells including those treated with sera from non-survivors (data not shown). These 
observations suggest that septic sera from non-survivors enhance P2X7 activity. 
 
Inhibition of pro-inflammatory pathways by septic sera 
Cell lysates were then subjected to the detection of cytosolic mediators associated with the 10 
ATP-dependent inflammasome pathway after exposure to ATP in the presence of patient sera. 
Intracellular ATP was slightly lower in macrophages treated with sera collected from septic patients 
on day 1 than in cells treated with sera from trauma patients (Fig. 5A). Accordingly, levels of 
inositol 1,4,5-triphosphate and cytosolic calcium were significantly lower in the former group than 
in the latter, as well as compared to those in cells exposed to sera from healthy controls (P < 0.01; 15 
Fig. 5B, C). However, these effects were largely absent in cells treated with sera collected on day 7 
from septic patients. In contrast, cyclic AMP levels were comparable among all cell groups (Fig. 
5D). Collectively, these data indicate that sera collected from septic patients at the time of 
admission suppress pro-inflammatory pathways upstream of NLRP3. 
 20 
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Sera from septic patients who did not survive suppress caspase-1 activation  
Pro-IL-1β, which is processed to form IL-1β following NLRP3 and caspase-1 activation, 
was slightly more abundant in cells treated with sera from septic patients collected on days 1 and 7 
than in cells exposed to sera from healthy controls or trauma patients (Fig. 6A). Conversely, active 
caspase-1 was significantly less abundant in macrophages treated with sera from septic patients 5 
collected on day 1 (P < 0.01), but not in cells stimulated with sera collected on day 7 from septic 
patients (Fig. 6B). However, the significant decrease in active caspase-1 was also observed in cells 
treated with sera collected on day 7 from patients who did not survive (P < 0.05; Fig. 6C). Similar 
trends were observed in terms of intracellular IL-1β levels (Fig. 6D, E). Taken together, these data 
suggest that activation of NLRP3 and caspase-1 in response to extracellular ATP is suppressed by 10 
factors that are present in sera from septic patients. This suppressive effect is clearly associated with 
prolonged immunoparalysis and poor clinical outcomes since it was found to be more pronounced 
in sera collected from patients who did not survive. 
 
Discussion 15 
Our data indicated that sera from septic patients suppress IL-1β production in 
macrophages stimulated with extracellular ATP, likely by antagonizing upstream NLRP3 or 
pro-inflammatory pathways. This suppressive effect peaked on day 3 after admission and 
persisted until day 7 among patients who did not survive, but was lost by day 7 among patients 
who survived. These observations suggest a new mechanism through which sepsis mediates 20 
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immunoparalysis, and partially support the prior hypothesis that persistent suppression of innate 
and adaptive immunity can cause late-stage death in septic patients (Hotchkiss et al. 2013).  
Inflammation and cell death in critically ill patients results in the abundant generation of 
DAMPs, which induce pro-inflammatory cytokine production (Cauwels et al. 2014; Stoffels et al. 
2015; Timmermans et al. 2016). Of the known DAMPs, extracellular ATP is one of the most potent. 5 
However, extracellular ATP might also suppress inflammation since its hydrolytic products are 
uniquely immunosuppressive (Borsellino et al. 2007; Beavis et al. 2012). In particular, ATP acts 
through purinergic P2 receptors (either the P2X cation-selective receptor channels or the P2Y 
metabotropic G protein-coupled receptors), thereby rapidly depleting regulatory T cells (Aswad et 
al. 2005), or modulating T cell activity (Ledderose et al. 2016). Conversely, hydrolytic products of 10 
ATP, such as adenosine monophosphate or adenosine, can induce the production of IL-10, an 
immunosuppressive cytokine, in a dose-dependent manner (Seo et al. 2004). They can also impair 
neutrophil chemotaxis and host defense during sepsis (Li et al. 2017). Therefore, ATP balance in the 
extracellular microenvironment is critical for the modulation of innate and adaptive immunity. 
Immunosuppressive factors have been detected in vivo and in vitro in sera from patients with 15 
active tuberculosis, cirrhosis, and solid tumors (Sherwin et al. 1979; Sugiyama et al. 1987; O'Brien 
et al. 2014; Kano 2015). In sera from septic patients, common immunosuppressive factors have also 
been detected, including IL-10, transforming growth factor β, and IL-4; these cytokines suppress 
pro-inflammatory mediators, tissue repair, T cell proliferation, and differentiation, among other 
functions, but also accelerate fibrosis and the development of T regulatory cells (Schulte et al. 20 
16 
 
2013). Similarly, in our study, septic sera that were collected during early clinical phases were 
found to contain immunosuppressive factors including IL-10, which is known to repress cytokine 
production in lipopolysaccharide-stimulated peritoneal macrophages (Fiorentino et al. 1991). 
However, the role of IL-10 in ATP-induced IL-1β production is unknown, especially since 
neutralizing antibodies to IL-10 did not affect the response of THP-1 macrophages to extracellular 5 
ATP (data not shown). Thus, sera from septic patients likely contain suppressive factors 
independent of IL-10. 
Our data also suggested that sera from septic patients who did not survive enhance P2X7 
uptake (Fig. 3D), which might partly explain the edema and cell swelling typically observed in 
septic patients. However, further studies are required to test this hypothesis. A lack of data regarding 10 
ATP trafficking is also a limitation of this study. For example, we observed that intracellular ATP 
levels were comparable upon stimulation with sera from septic patients who survived and those 
from non-survivors, probably as a result of autoregulatory mechanisms in the cytosol. Such 
mechanisms include the opening of pannexin pores to release ATP and IL-1β into the extracellular 
space, as well as feedback regulation by adenosine, which itself is regulated by membrane-bound 15 
nucleotide transporters and by intracellular adenosine kinase (Baron et al. 2015). Finally, the 
number of non-surviving patients was too small to investigate the relationship between a potential 
novel mechanism of immunoparalysis and mortality. Thus, we recommend larger multicenter 
studies, especially using non-survivors. 
 20 
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Conclusion 
In conclusion, we show that immunoparalysis in septic patients could be caused by serum 
factor(s) that suppress the inflammatory IL-1β response to extracellular ATP by inhibiting caspase-1 
activation in innate immune cells. Such suppressive factors might be correlated with fatal outcomes. 
 5 
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Table 1. Baseline characteristics of cohorts. 
Parameters Controls 
(n = 5) 
Trauma 
(n = 10) 
Sepsis 
(n = 49) 
Age, y 
Men 
Sepsis/severe sepsis and septic shock  
Injury severity score 
67 ± 6 
4 (80) 
NA 
NA 
68 ± 10 
6 (60) 
NA 
35 [25–42] 
68 ± 14 
25 (51) 
13/36 
NA 
Head and neck injury, region 1  
Facial, region 2 
Chest, region 3 
Extremities, region 5 
NA 
NA 
NA 
NA 
4 (40) 
1 (10) 
3 (30) 
2 (20) 
NA 
NA 
NA 
NA 
Site of original infection 
Abdomen  
Central nervous system 
Respiratory  
Soft tissue  
Urinary tract  
Others  
Undetermined 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
 
11 (28) 
1 (3) 
5 (13) 
13 (33) 
10 (26) 
3 (8) 
6 (15) 
Serum concentrations, mg/L 
C-reactive protein 
Procalcitonin 
Lactate 
Scores 
Acute Physiologic Assessment and Chronic Health Evaluation II 
Sequential Organ Failure Assessment Score 
Disseminated Intravascular Coagulation 
Mean score 
Numbers of patients with disseminated intravascular coagulation 
Survivors 
Days in intensive care unit 
 
NA 
NA 
NA 
 
NA 
NA 
 
NA 
NA 
5 (100) 
NA 
 
0.19 ± 0.05 
Not measured 
1.9 ± 0.3 
 
4.6 ± 1.2 
5.3 ± 2.5 
 
3.0 ± 1.2 
3 (30) 
10 (100) 
6 [4–13] 
 
17.8 ± 11.0 
8.7 [2.0–10.0] 
5.3 ± 4.9 
 
20.8 ± 8.5 
8.7 ± 4.7 
 
4.2 ± 2.1 
27 (55) 
39 (80) 
12 [7–21] 
Data are mean ± SD, median [IQR], or number of observations (%). 
NA, not applicable. 
Disseminated Intravascular Coagulation was calculated based on JAAM-DIC 2016 
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Table 2. Baseline characteristics of septic patients. 
Parameters Survivors 
(n = 39) 
Non-survivors 
(n = 10) 
P 
Age, y 66 ± 1 72 ± 10  
Women  19 (49) 5 (50)  
Sepsis classification at admission    
Uncomplicated sepsis   13 (33) -  
Severe sepsis 6 (15) 1 (10)  
Septic shock 20 (52) 9 (90)  
Site of original infection 
Abdomen 
Central nervous system 
Respiratory  
Soft tissue  
Urinary tract  
Others  
Undetermined  
 
7 (18) 
1 (3) 
3 (8) 
13 (33) 
9 (22) 
3 (8) 
3 (8) 
 
4 (40) 
- 
2 (20) 
- 
1 (10) 
- 
3 (30) 
 
 
 
 
 
 
 
 
Serum concentrations, mg/L 
C-reactive protein 
 
19.0 ± 11.2 
 
13.4 ± 9.3 
 
0.14 
Procalcitonin, median [IQR] 6.8 [1.5–10.3] 27.8 [24.2–51.3] < 0.001 
Lactate 3.5 ± 2.2 12.0 ± 4.1 < 0.0001 
Score 
Acute Physiologic Assessment and Chronic Health 
Evaluation II  
 
18.8 ± 7.2 
 
28.8 ± 10.2 
 
< 0.0001 
Sequential Organ Failure Assessment  7.6 ± 3.4 13.3 ± 5.7 < 0.0001 
Disseminated Intravascular Coagulation
Mean ± SD 
n (%) 
 
3.9 ± 1.2 
18/21 (46) 
 
5.6 ± 2.8 
9 (90) 
 
0.023 
Days spent in ICU, no [IQR]  13 [7–21] 12 [5–18]  
Unless specified otherwise, values are mean ± SD or numbers of observations (%). 
Disseminated Intravascular Coagulation was calculated based on JAAM-DIC 2016. 
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Figure legends 
Fig. 1. Concentration of cytokines and chemokines in sera from septic patients and control 
individuals. 
Sera collected at the time of patient admission were screened by bead-based fluorescence assays 
to quantify inflammatory cytokines, with a limit of quantification of 0.6 pg/mL. Individual 5 
serum samples were assayed in duplicate and averaged (healthy controls, n = 5; trauma patients, 
n = 10; sepsis patients, n = 49). *P < 0.05; **P < 0.01 by Mann-Whitney U test. 
Fig. 2. IL-1β secretion is suppressed in THP-1 macrophages exposed to septic sera. 
A–D. IL-1β secretion after an 8-h exposure to sera diluted 60u and supplemented without 
damage-associated molecular pattern molecules (A) or with 2 mM ATP (B), 200 mg/mL 10 
monosodium urate (C), and 1 μg/mL HMGB1 (D). THP-1 macrophages were treated with 
RPMI supplemented without (untreated) or with the indicated agent and sera diluted 60u. 
Individual serum samples were assayed in triplicate and averaged (healthy controls, n = 5; 
trauma patients, n = 10; sepsis patients, n = 49). **P < 0.01 by Mann-Whitney U test. 
Fig. 3. Septic sera specifically suppress ATP-induced IL-1β production in THP-1 macrophages. 15 
A, B. IL-1β secretion after an 8-h exposure to sera collected on days 1, 3, and 7 from septic 
patients who did (open bars) or did not survive (filled bars), which was supplemented with 2 
mM ATP (A) or 200 mg/mL monosodium urate (MSU) (B). Macrophages were treated with 
RPMI supplemented without (untreated) or with the indicated agent and sera diluted 60u. 
Individual sera were assayed in triplicate and averaged (sepsis survivors on day 1, n = 39; sepsis 20 
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non-survivors on day 1, n = 10; sepsis survivors on day 3, n = 16; sepsis non-survivors on day 3, 
n = 4; sepsis survivors on day 7, n = 16; sepsis non-survivors on day 7, n = 4). *P < 0.05, by F2 
test. 
Fig. 4. Sera from septic patients who did not survive activate P2X7 uptake. 
A–B. ATP in the culture supernatant was quantified by a luciferin-luciferase assay using the 5 
supernatant of macrophages exposed to ATP and sera for 8 h (A) and in sera collected at the 
time of patient admission (B). C. Cells treated with ATP and sera were also treated with 
YO-PRO-1 dye and analyzed by flow cytometry. D. Cells treated with ATP and sera from septic 
patients who did (clear bars) or did not survive (filled bars) were incubated with YO-PRO-1 dye 
and analyzed by flow cytometry. Macrophages were treated with RPMI supplemented without 10 
(untreated) or with the indicated agent and sera diluted 60u. Individual sera were tested in 
triplicate and averaged (healthy controls, n = 5; trauma patients, n = 10; sepsis patients on day 1, 
n = 49; sepsis patients on day 7, n = 20; sepsis survivors on day 1, n = 39; sepsis non-survivors 
on day 1, n = 10; sepsis survivors on day 7, n = 16; sepsis non-survivors on day 7, n = 4). *P < 
0.05 by Mann-Whitney U test; n.s., not significant by ANOVA. 15 
Fig. 5. Suppression of intracellular signaling mediators upstream of NLRP3 by sera from septic 
patients. 
Lysates from macrophages exposed to ATP and sera were assayed by ELISA for intracellular 
ATP (A), inositol 1,4,5-triphosphate (B), cytosolic calcium (C), and cyclic AMP (D). 
Macrophages were treated with RPMI supplemented without (untreated) or with the indicated 20 
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agent and sera diluted 60u. Individual sera were assayed in triplicate and averaged (healthy 
controls, n = 5; trauma patients, n = 10; sepsis patients on day 1, n = 49; sepsis patients on day 7, 
n = 20). *P < 0.05; **P < 0.01 by Mann-Whitney U test orF2 test. 
Fig. 6. Sera from septic patients who did not survive suppress active caspase-1 in macrophages. 
A, B. Pro-IL-1β (A) and activated caspase-1 (B) expression in cells treated with ATP and sera 5 
for 8 h. C. Production of active caspase-1 in cells treated with ATP and sera collected at the time 
of admission and on day 7 from septic patients who did (clear bars) or did not survive (filled 
bars). D. Production of intracellular IL-1β in cells treated for 8 h with ATP and sera. E. 
Production of intracellular IL-1β in cells treated for 8 h with ATP and sera collected at the time 
of patient admission and on day 7 from sepsis patients who did (clear bars) and did not survive 10 
(filled bars). Macrophages were treated with RPMI supplemented without (untreated) or with 
the indicated agent and sera diluted 60u. Individual serum samples were assayed in triplicate 
and averaged (healthy controls, n = 5; trauma patients, n = 10; sepsis patients on day 1, n = 49; 
sepsis patients on day 7, n = 20; sepsis survivors on day 1, n = 39; sepsis non-survivors on day 1, 
n = 10; sepsis survivors on day 7, n = 16; sepsis non-survivors on day 7, n = 4). *P < 0.05; **P 15 
< 0.01 by Mann-Whitney U test orF2 test. 
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